

## Workshop

## CLINICAL MARKERS AND RISK FACTORS FOR CARDIOVASCULAR DISEASE

Chairpersons: **Pines A.** (Tel Aviv, Israel)  
**Zambon A.** (Padua, Italy)

hour:		abstract bk. page ref.:
14.00	CARDIOVASCULAR PROTECTION: IS POSTMENOPAUSAL HORMONE THERAPY NO LONGER AN OPTION? <b>van der Mooren M.J.</b> (Amsterdam, The Netherlands)	<b>2</b>
14.20	OXIDATIVE STRESS CONTRIBUTES TO REDUCED LARGE ELASTIC ARTERY COMPLIANCE IN ESTROGEN-DEFICIENT POSTMENOPAUSAL WOMEN <b>Moreau K.L.</b> , Plum A.E., Gavin K., Seals D.R. (Boulder and Denver, CO, USA)	<b>2</b>
14.35	HEART DISEASE RISK DETERMINES MENOPAUSAL AGE RATHER THAN REVERSE Kok H.S., van Asselt K.M., <b>van der Schouw Y.T.</b> , van der Tweel I., Peeters P.H.M., Wilson P.W.F., Pearson P.L., Grobbee D.E. (Utrecht, The Netherlands and Boston, MA, USA)	<b>2</b>
14.50	DIVERGENT EFFECTS OF SYNTHETIC PROGESTINS ON ENDOTHELIAL NITRIC OXIDE SYNTHASE <b>Simoncini T.</b> , Mannella P., Fornari L., Varone G., Caruso A., Genazzani A.R. (Pisa, Italy)	<b>2</b>
15.05	OPPOSITE MODULATION OF INFLAMMATORY ENZYMES BY ESTROGEN AND RESVERATROL IN VASCULAR SMOOTH MUSCLE CELLS <b>Cignarella A.</b> , Minici C., Bolego C., Pinna C., Crippa M., Puglisi L. (Milan, Italy)	<b>3</b>
15.20	HIGH MW FGF2, BUT NOT LOW MW FGF2 NOR VEGF, MEDIATES THE EFFECT OF ESTRADIOL ON REENDOTHELIALIZATION Garmy-Susini B., Delmas E., Gourdy P., Zhou M., Brouchet L., Mugniot A., Bayard F., Prats A.C., Doetschman T., Prats H., <b>Arnal J.F.</b> (Toulouse, France and Cincinnati, OH, USA)	<b>3</b>
15.35	<i>End of the Session</i>	
15.35 - 16.00	<i>Break</i>	